) is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.
The biotech firm has enjoyed the spotlight as its brand-new platform became a frontrunner, and ultimately one of the two key vaccines, in addressing the pandemic. Since the multibillion-dollar COVID windfall, investors have been anxious about the near-term prospects of Moderna.
Hoge said it will take a reasonable outlook, but notes the company is already up to three vaccines in two years and has late-stage trial data expected for three more in the near term. But it's also important to note that Moderna's current pipeline is mainly respiratory vaccines, which will not provide the type of profits to make up for the loss in the COVID portfolio.
Still, he noted that much of the company's investment is now in clinical trials, and he expects the newer products to add to the company's revenues sooner rather than later.